Biodistribution and individual dosimetry of I-131-labeled Rituximab in relapsed non-Hodgkin's lymphoma

被引：0
|
作者：
Scheidhauer, K
Wolf, I
von Schilling, C
Schmidt, B
Baumgartl, H
Reidel, G
Peschel, C
Schwaiger, M
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, D-8000 Munich, Germany
[2] Tech Univ Munich, Med Klin 3, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2001年 / 28卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OS79
引用
收藏
页码：981 / 981
页数：1
相关论文
共 50 条
  • [31] Rituximab combinations in the treatment of non-Hodgkin's lymphoma
    Leonard, John P.
    CANCER INVESTIGATION, 2007, 25 : 43 - 44
  • [32] Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma - Reply
    Britton, KE
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (12) : 2127 - 2127
  • [33] Impact of full dose of rituximab on pharmacokinetics and dosimetry of Zevalin for patients with non-Hodgkin's lymphoma
    Shen, S
    Forero, A
    Meredith, RF
    LoBoglio, AF
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S426 - S426
  • [34] ANALYSIS OF A PHASE 2 STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    DeRoock, I.
    Chee, K.
    O'Donnell, R.
    Quirch, C.
    Reed-Pease, C.
    Tuscano, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 118 - 118
  • [35] REPEATED RADIOIMMUNOTHERAPY (RIT) WITH I-131 RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS
    Kang, H. J.
    Lim, S. M.
    Cheon, G. J.
    Choi, C. W.
    Lee, S. S.
    Kim, W. S.
    Park, Y. H.
    Ryoo, B.
    Na, I. I.
    Yang, S. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 232 - 232
  • [36] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    ANNALS OF ONCOLOGY, 2006, 17 : 200 - 200
  • [37] REPEATED RADIOIMMUNOTHERAPY (RIT) WITH I-131 RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS
    Kang, H. J.
    Lim, S. M.
    Cheon, G. J.
    Choi, C. W.
    Lee, S. S.
    Na, I. I.
    Ryoo, B. Y.
    Kim, W. S.
    Nam, S. H.
    Park, Y. H.
    Suh, C.
    Eom, H. S.
    Yang, S. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 100 - 100
  • [38] Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
    Boland, A.
    Bagust, A.
    Hockenhull, J.
    Davis, H.
    Chu, P.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 48
  • [39] Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
    Leahy, Michael F.
    Seymour, John F.
    Hicks, Rodney J.
    Turner, J. Harvey
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4418 - 4425
  • [40] Options: Relapsed and refractory non-Hodgkin's lymphoma
    Friedberg, Jonathan W.
    CANCER INVESTIGATION, 2007, 25 : 36 - 37
12345